Skip to main content
Contribution to Book
Somatic Mutations and Immunotherapy
Immunotherapy in Translational Cancer Research (2018)
  • Eric Tran, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
Immunotherapies that harness the endogenous immune response such as interleukin‐2, adoptive T cell transfer, and inhibitors to immune checkpoints can mediate durable tumor regression in some patients with metastatic solid cancers. Recent advances in high throughput nucleic acid sequencing technologies in combination with immunological screening assays have provided evidence that T cells targeting the protein products of random somatic mutations expressed by the patient's tumors, known as neoantigens, are likely responsible for mediating tumor regressions in some patients treated with immunotherapy. These observations, along with the fact that neoantigens are truly tumor specific, suggest that the development of immunotherapies that potently target unique neoantigens expressed by a patient's autologous tumors may enhance clinical response in patients with metastatic cancers.
  • neoantigen,
  • neoepitope,
  • somatic mutation,
  • immunotherapy,
  • T cell,
  • adoptive T cell therapy,
  • checkpoint inhibitor,
  • PD‐1,
  • CTLA‐4
Publication Date
February 14, 2018
Laurence J. N. Cooper MD, PhD,Elizabeth A. Mittendorf MD, PhD,Judy Moyes MB, BChir, FRCP(C), FRCPCH,Sabitha Prabhakaran PhD,
John Wiley & Sons, Inc.
Citation Information
Eric Tran. "Somatic Mutations and Immunotherapy" Hoboken, N,J,Immunotherapy in Translational Cancer Research (2018) p. 24 - 36
Available at: